Compare · BDX vs TNDM
BDX vs TNDM
Side-by-side comparison of Becton Dickinson and Company (BDX) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $42.51B, about 32.0x TNDM ($1.33B).
- BDX has been more active in the news (15 items in the past 4 weeks vs 5 for TNDM).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Tandem Diabetes Care Inc.
- Price
- -
- -
- Market cap
- $42.51B
- $1.33B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 15
- 5
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest BDX
- BD Achieves Excellence in Employee Well‑Being, Earning Top Industry Recognition
- Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,244 worth of shares (74 units at $151.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,159 units (SEC Form 4)
- BD to Present at Bank of America Securities Health Care Conference
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
Latest TNDM
- Tandem Diabetes Care Announces Upcoming Conference Presentations
- Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
- SEC Form 4 filed by Kyrillos Jean-Claude
- SEC Form DEF 14A filed by Tandem Diabetes Care Inc.
- SEC Form DEFA14A filed by Tandem Diabetes Care Inc.
- Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
- SEC Form PRE 14A filed by Tandem Diabetes Care Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Tandem Diabetes Care Inc.
- Tandem Diabetes Care upgraded by Truist with a new price target
- SEC Form 4 filed by Novara Mark David